Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 201–300 of 999
Pharithi, R. B., Vallverdú, M. F., Maisel, A. S., O'Connell, E., Walshe, M., Sweeney, C. M., Barton, J. C., McDonald, K. E., O'Hare, D., Watson, C. J., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12547 · Cited by 32
Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
Lala, A., HAMO, C. E., Bozkurt, B., Fiuzat, M., Blumer, V. L., Bukhoff, D., Butler, J., Costanzo, M. R., Felker, G. M., Filippatos, G. S., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.09.030 · Cited by 37
Nguyen, D. V., Le, T. N., Truong, B. Q., & Nguyen, H. T. T. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3454 · Cited by 34
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
Dewan, P., Docherty, K. F., & McMurray, J. J. V. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0136 · Cited by 35
Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure
Grosman‐Rimon, L., Billia, F., Wright, E., Carasso, S., Elbaz‐Greener, G., Kachel, E., Rao, V. A., & Cherney, D. Z. I. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09860-8 · Cited by 36
ARNI in Cardiovascular Disease: Current Evidence and Future Perspectives
Kuchulakanti, P. K. (2020) · Future Cardiology · doi:10.2217/fca-2019-0089 · Cited by 34
Evidence-Based Management of Acute Heart Failure
Gupta, A., Tomasoni, D., Sidhu, K., Metra, M., & Ezekowitz, J. A. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.002 · Cited by 41
Recent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 39
Abdin, A., Bauersachs, J. K., Soltani, S., Eden, M., Frey, N., & Böhm, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14197 · Cited by 34
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow, D. A., Velazquez, E. J., Desai, A. S., DeVore, A. D., Lepage, S., Park, J., Sharma, K., Solomon, S. D., Starling, R. C., Ward, J. H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.027 · Cited by 43
Self-citationKhandwalla, R. M., Grant, D., Birkeland, K. T., Heywood, J. T., Fombu, E., Owens, R. L., Steinhubl, S. R., & for the AWAKE-H. F. Study Investigators (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00440-y · Cited by 30
Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure
Vader, J. M., Givertz, M. M., Starling, R. C., McNulty, S. E., Anstrom, K. J., Desvigne-Nickens, P. M., Hernandez, A. F., Braunwald, E., & Mann, D. L. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.04.013 · Cited by 38
Zhang, Y., Gao, C., Greene, S. J., Greenberg, B., Butler, J., Yu, J., Zheng, Z., Ma, G., Wang, L. Y., Yang, P. C., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14184 · Cited by 32
Mentz, R. J., Ward, J. H., Hernandez, A. F., Lepage, S., Morrow, D. A., Sarwat, S., Sharma, K., Solomon, S. D., Starling, R. C., Velazquez, E. J., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.02.001 · Cited by 31
Self-citationČerlinskaitė‐Bajorė, K., Lam, C. S. P., Sliwa, K. S., Adamo, M., ter Maaten, J. M., Léopold, V., Mebazaa, A., Davison, B. A., Edwards, C., Arrigo, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2882 · Cited by 32
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Lala, A., Coca, S. G., Feinman, J., HAMO, C. E., Fiuzat, M., Abraham, W. T., O’Connor, C. M., Lindenfeld, J., Januzzi, J. L., Cavagna, I., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.041 · Cited by 34
Oliveros, E., Oni, E., Shahzad, A., Kluger, A. Y., Lo, K. B., Rangaswami, J., & McCullough, P. A. (2020) · Cardiorenal Medicine · doi:10.1159/000504167 · Cited by 30
de la Espriella, R., Santas, E., Reiriz, I. Z., Górriz, J. L., Marcos, M. C., & Núñez, J. E. (2021) · Nefrología · doi:10.1016/j.nefro.2021.04.006 · Cited by 49
Zhao, J., Zeng, Y., & Shen, X. (2021) · Clinical Cardiology · doi:10.1002/clc.23717 · Cited by 29
Liang, W. H., Xie, B., Ding, P., Wang, M., Yuan, J., Cheng, X. C., Liao, Y., & Yu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.727838 · Cited by 31
Sacubitril/Valsartan Attenuates Atrial Structural Remodelling in Atrial Fibrillation Patients
Liu, Y., Zhang, M., Hao, Z., Wang, N., & Zhang, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13937 · Cited by 30
Bayés‐Genís, A., Aimo, A., Metra, M., Anker, S. D., Seferovic, P. M., Rapezzi, C., Castiglione, V., Núñez, J. E., Emdin, M., Rosano, G. M. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2542 · Cited by 31
Moghaddam, N., Hawkins, N. M., McKelvie, R. S., Poon, S., Joncas, S. X., MacFadyen, J. R., Honos, G. N., Wang, J., Rojas‐Fernandez, C. H., Kok, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.013 · Cited by 31
Butler, J., Packer, M., Greene, S. J., Fiuzat, M., Anker, S. D., Anstrom, K. J., Carson, P. E., Cooper, L. B., Fonarow, G. C., Hernandez, A. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042155 · Cited by 30
Safety of Sacubitril/Valsartan Initiated During Hospitalization: Data from a Non-Selected Cohort
López‐Azor, J. C., Vicent, L., Valero‐Masa, M. J., Esteban‐Fernández, A., Gómez-Bueno, M. F., Pérez-Rivera, J.-Á., Díez‐Villanueva, P., Bagudá, J. D. J., Manuel‐Iniesta, Á., Bover, R., et al. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12527 · Cited by 28
Nakamura, T., & Tsujita, K. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.03.004 · Cited by 36
Heart Failure Pharmacological Management: Gaps and Current Perspectives
Severino, P., D’Amato, A., Prosperi, S., Myftari, V., Canuti, E. S., Francia, A. L., Cestiè, C., Maestrini, V., Lavalle, C., Badagliacca, R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031020 · Cited by 30
Wen, Z., Zhan, J., Li, H., Xu, G., Ma, S., Zhang, J., Li, Z., Ou, C., Yang, Z., Cai, Y., et al. (2021) · Theranostics · doi:10.7150/thno.53644 · Cited by 30
Raffaello, W. M., Henrina, J., Huang, I., Lim, M. A., Suciadi, L. P., Siswanto, B. B., & Pranata, R. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.20 · Cited by 37
Heart failure population health considerations
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88673 · Cited by 35
Greene, S. J., Choi, S., Lippmann, S., Mentz, R. J., Greiner, M. A., Hardy, N. C., Hammill, B. G., Luo, N., Samsky, M. D., Heidenreich, P. A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021459 · Cited by 29
Gaziano, L., Cho, K., Djoussé, L., Schubert, P. L., Galloway, A., Ho, Y.-L. A., Kurgansky, K. E., GAGNON, D. R., Russo, J. P., Angelantonio, E. D., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13429 · Cited by 28
Saxena, S., Goldenberg, I., McNitt, S. A., Hsich, E., Kutyifa, V., Bragazzi, N. L., Polonsky, B., Aktaş, M. K., Huang, D. T.-C., Rosero, S. Z., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.17153 · Cited by 27
Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang
Feygina, E. E., Katrukha, A., & Semenov, A. G. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919110105 · Cited by 28
Margolin, E., Huynh, T., Brann, A. M., & Greenberg, B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2023.100818 · Cited by 28
Shetty, S. S., Malik, A. H., Ali, A., Yang, Y. C., Briasoulis, Α., & Alvarez, P. A. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.01.060 · Cited by 26
King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 30
Effect of Carperitide on the 1 Year Prognosis of Patients with Acute Decompensated Heart Failure
Nogi, K., Ueda, T., Matsue, Y., Nogi, M., Ishihara, S., Nakada, Y., Kawakami, R., Kagiyama, N., Kitai, T., Oishi, S., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13770 · Cited by 26
Management of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 35
Self-citationFuertes-Kenneally, L., Lorenzo, M., Romero-González, G. A., Marcos, M. C., Núñez, G., Górriz, J. L., Barrios, A. G., Fudim, M., de la Espriella, R., & Núñez, J. E. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad031 · Cited by 34
Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide
Meems, L. M. G., Andersen, I. A., Pan, S., Harty, G. J., Chen, Y., Zheng, Y., Harders, G. E., Ichiki, T., Heublein, D. M., Iyer, S. R., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12012 · Cited by 26
Kittleson, M. M., Breathett, K. K., Ziaeian, B., Aguilar, D. A., Blumer, V. L., Bozkurt, B., Diekemper, R. L., Dorsch, M. P., Heidenreich, P. A., Jurgens, C. Y., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000132 · Cited by 36
National Trends in the Use of Sacubitril/Valsartan
Ozaki, A. F., Krumholz, H. M., Mody, F. V., & Jackevicius, C. A. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.05.015 · Cited by 25
Lelonek, M., Grabowski, M., Kasprzak, J. D., Leszek, P., Nessler, J., Pawlak, A., Rozentryt, P., Straburzyńska‐Migaj, E., & Rubiś, P. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0021 · Cited by 32
Wang, X., Zhang, C., & Editing Group of the Chinese Expert Consensus on the Diagnosis and Treatment of Chronic Heart Failure in Elderly Patients (2022) · Aging Medicine · doi:10.1002/agm2.12215 · Cited by 27
Tanaka, A., Kida, K., Matsue, Y., Imai, T., Suwa, S., Taguchi, I., Hisauchi, I., Teragawa, H., Yazaki, Y., Moroi, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae561 · Cited by 26
Георгиевна, В. Н., Polyakov, D. S., & Fomin, I. V. (2020) · Kardiologiia · doi:10.18087/cardio.2020.3.n1002 · Cited by 32
Zhang, Y., Wu, Y., Zhang, K., Ke, Z., Hu, P. C., & Jin, D. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000000955 · Cited by 28
Essandoh, K., Subramani, A., Ferro, O. A., Teuber, J. P., Koripella, S., & Brody, M. J. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.11.003 · Cited by 23
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 30
Matsumoto, S., McMurray, J. J. V., Nasu, T., Ishii, S., Kagiyama, N., Kida, K., Fujimoto, W., Kikuchi, A., Ijichi, T., Shibata, T., et al. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.11.005 · Cited by 30
Sacubitril-Valsartan in Patients Requiring Hemodialysis
Le, D., Grams, M. E., Coresh, J., & Shin, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.29237 · Cited by 28
Chioncel, O. D., Mebazaa, A., Farmakis, D. T., Abdelhamid, M., Lund, L. H., Harjola, V., Anker, S. D., Filippatos, G., Gal, T. B., Damman, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3673 · Cited by 26
Jefferies, J. L., Mazur, W. M., Howell, C. R., Plana, J. C., Ness, K. K., Li, Z., Joshi, V. M., Green, D. M., Mulrooney, D. A., Towbin, J. A., et al. (2021) · Cancer · doi:10.1002/cncr.33860 · Cited by 27
Liu, X., Liu, H., Wang, L., Zhang, L., & Xu, Q. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263131 · Cited by 27
The history and mystery of sacubitril/valsartan: From clinical trial to the real world
Zhang, M., Zou, Y., Li, Y., Wang, H., Sun, W., & Liu, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1102521 · Cited by 29
Treatment Strategies of Improving Quality of Care in Patients With Heart Failure
Kim, S.-E., & Yoo, B. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0024 · Cited by 28
Impact of Sacubitril-Valsartan on Markers of Glomerular Function
Tersalvi, G., Dauw, J., Martens, P., & Müllens, W. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00463-1 · Cited by 25
Kittleson, M. M., Breathett, K. K., Ziaeian, B., Aguilar, D. A., Blumer, V. L., Bozkurt, B., Diekemper, R. L., Dorsch, M. P., Heidenreich, P. A., Jurgens, C. Y., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.014 · Cited by 31
Machine Learning in Cardiology—Ensuring Clinical Impact Lives Up to the Hype
Russak, A. J., Chaudhry, F., Freitas, J. K. D., Baron, G., Chaudhry, F. F., Bienstock, S., Paranjpe, I., Vaid, A., Ali, M., Zhao, S., et al. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420928651 · Cited by 31
Savarese, G., Hage, C., Benson, L., Schrage, B., Thorvaldsen, T., Lundberg, A., Fudim, M., Linde, C. M., Dahlström, U., Rosano, G. M. C., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13165 · Cited by 25
Volpe, M., Bauersachs, J. K., Bayés‐Genís, A., Butler, J., Solal, A. C., Gallo, G., Deichl, A. S., Khan, M. S., Battistoni, A., Pieske, B. M., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.071 · Cited by 23
Chen, D., Chen, C.-C., Tseng, C., Chen, S., Chang, S., Huang, W., Wen, M., Hsieh, M., & Hsieh, I.-C. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101149 · Cited by 27
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial
Spall, H. G. C. V., DeFilippis, E. M., Lee, S. F., Oz, U. E., Perez, R., Healey, J. S., Allen, L. A., Voors, A. A., Ko, D. T., Thabane, L., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008548 · Cited by 25
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Zhang, R., Sun, X., Li, Y., He, W.-Z., Zhu, H., Liu, B., & Zhang, A. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211058681 · Cited by 34
Filardi, P. P., Paolillo, S., Agostoni, P., Basile, C., Basso, C., Barillà, F., Correale, M., Curcio, A., Mancone, M., Merlo, M., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.04.006 · Cited by 23
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0047 · Cited by 23
Foà, A., Vaduganathan, M., Claggett, B. L., Pabón, M. A., Lu, H. Y., Pfeffer, M. A., Packer, M., Vardeny, O., Rouleau, J. L., Lefkowitz, M. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.035 · Cited by 25
Fudim, M., Sayeed, S., Xu, H., Matsouaka, R., Heidenreich, P. A., Velazquez, E. J., Yancy, C. W., Fonarow, G. C., Hernandez, A. F., & DeVore, A. D. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006645 · Cited by 23
Self-citationDiabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management
Chen, D., Sindone, A. P., Huang, M., Peter, K., & Jenkins, A. J. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.013 · Cited by 27
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy
Malek, V., Sharma, N., & Gaikwad, A. B. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.05.008 · Cited by 22
Mentz, R. J., DeVore, A. D., Tasissa, G., Heitner, J. F., Piña, I. L., Lala, A., Cole, R., Lanfear, D., Patel, C. B., Ginwalla, M. B., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2019.12.024 · Cited by 23
Self-citationNeprilysin as a Biomarker: Challenges and Opportunities
Pavo, N., Prausmüller, S., Bartko, P. E., Goliasch, G., & Hülsmann, M. (2020) · Cardiac failure review · doi:10.15420/cfr.2019.21 · Cited by 24
Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
Singhania, N., Bansal, S. K., Mohandas, S., Nimmatoori, D. P., Ejaz, A. A., & Singhania, G. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-3 · Cited by 25
Bellis, A., Mauro, C., Barbato, E., Trimarco, B., & Morisco, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228612 · Cited by 22
Monosilio, S., Filomena, D., Luongo, F., Sannino, M., Cimino, S., Neccia, M., Mariani, M. V., Birtolo, L. I., Benedetti, G., Tonti, G., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.883769 · Cited by 24
Zhou, W., Yang, X., Jin, J., Cheng, M., Li, Y., Bai, Y., & Xu, J. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03599-w · Cited by 26
Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction
Grewal, P. K., Abboud, A., Myserlis, E. P., Goldschmidt, M., Butler, J., Skopicki, H. A., & Kalogeropoulos, A. P. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100372 · Cited by 26
Nyimanu, D., Kay, R. G., Šulentić, P., Kuc, R. E., Ambery, P., Jermutus, L., Reimann, F. M., Gribble, F. M., Cheriyan, J., Maguire, J. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56157-9 · Cited by 22
Luo, N., Lippmann, S., Mentz, R. J., Greiner, M. A., Hammill, B. G., Hardy, N. C., Laskey, W. K., Heidenreich, P. A., Chang, C., Hernandez, A. F., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010484 · Cited by 20
Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J., Lee, H., Hwang, K., Kim, K. H., et al. (2019) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0007 · Cited by 21
de Frutos, F., Mirabet, S., Ortega‐Paz, L., Buera, I., Darnés, S., Farré, N., Perez-Villa, B., Adeliño, R., Claret, R. B., Pérez‐Rodon, J., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12567 · Cited by 22
Abumayyaleh, M., El‐Battrawy, I., Behnes, M., Borggrefe, M. M., & Akın, İ. (2020) · Future Cardiology · doi:10.2217/fca-2020-0002 · Cited by 24
Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis
Vasquez, N., Carter, S. J., & Grodin, J. L. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00458-y · Cited by 25
Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances
Tang, W. H. W., & Kiang, A. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01384-0 · Cited by 22
Armentaro, G., D’Arrigo, G., Magurno, M., Toscani, A. F., Condoleo, V., Miceli, S., Cassano, V., Maio, R., Arturi, F., Tripepi, G. L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733475 · Cited by 24
Neues zur Diagnostik und Therapie der Herzinsuffizienz
Wintrich, J., Berger, A.-K., Bewarder, Y., Emrich, I. E., Slawik, J., & Böhm, M. (2021) · Herz · doi:10.1007/s00059-021-05062-x · Cited by 41
Kusunose, K., Imai, T., Tanaka, A., Dohi, K., Shiina, K., Yamada, T., Kida, K., Eguchi, K., Teragawa, H., Takeishi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01380-w · Cited by 22
Ortiz, C., Klein, S., Reul, W., Magdaleno, F., Gröschl, S., Dietrich, P., Schierwagen, R., Uschner, F. E., Torres, S., Hieber, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112059 · Cited by 22
Oskouie, S. K., Pandey, A., Sauer, A. J., Greene, S. J., Müllens, W., Khan, M. S., Quinn, K. L., Ho, J. E., Albert, N. M., & Spall, H. G. C. V. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101131 · Cited by 26
Ganesananthan, S., Shah, N., Shah, P. P., Elsayed, H., Phillips, J., Parkes, A., Morgan, A. R., & Yousef, Z. R. (2020) · Open Heart · doi:10.1136/openhrt-2020-001305 · Cited by 24
Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
Rahamim, E., Nachman, D., Yagel, O., Yarkoni, M., Elbaz‐Greener, G., Amir, O., & Asleh, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194409 · Cited by 24
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction
Greenberg, B. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0401 · Cited by 26
Improving implementation of evidence‐based therapies for heart failure
DeVore, A. D., Bosworth, H. B., & Granger, B. B. (2022) · Clinical Cardiology · doi:10.1002/clc.23845 · Cited by 22
Self-citationZhang, H., & Liu, Z. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5734876 · Cited by 21
RetractedSpoto, S., Argemí, J., Costanzo, R. D., Gómez, J. J. G., González, N. S., Basili, S., Cangemi, R., Abbate, A., Locorriere, L., Masini, F., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071155 · Cited by 22
Angiotensin-Converting Enzyme and Heart Failure
Álvarez-Zaballos, S., & Martínez‐Sellés, M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807150 · Cited by 26
Reddy, Y. N. V., Borlaug, B. A., O’Connor, C. M., & Gersh, B. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz364 · Cited by 24
Bellis, A., Mauro, C., Barbato, E., Gioia, G. D., Sorriento, D., Trimarco, B., & Morisco, C. (2020) · Cells · doi:10.3390/cells9092134 · Cited by 21
Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach
Fabris, E., Merlo, M., Rapezzi, C., Ferrari, R., Metra, M., Frigerio, M., & Sinagra, G. (2019) · Drugs · doi:10.1007/s40265-019-01181-2 · Cited by 26
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.